Patent US5298019A successfully refreshed from Google Patents.
US5298019A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Controlled administration of chemodenervating pharmaceuticals
Assignee: Revance Therapeuticals Inc
•
Filing: 1993-01-13
•
Granted: 1994-03-29
•
Expires: 2013-01-13
Abstract
Abstract This invention relates to a method for controlled administration of chemodernervating agents such as botulinum toxin-derived pharmaceutical, useful in attenuating neural stimulation and spasmodic activity of muscle. The method involves administration of novel dosage forms based upon the standardization of denervating pharmaceuticals. The invention also relates to novel methods of administrating chemodernervating agents in a controlled and reproducible manner so as to confine their effects to a given region of muscle mass while minimizing in adjacent muscle tissue.
Inventors
- 👤 Gary E. Borodic
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 21:57
CPC Classifications
A; A61; A61K; A61K8/00; A61K8/18; A61K8/30; A61K8/64; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61K38/4886; A61K38/4893; A61K8/96; A61K8/99; A61Q; A61Q19/00; A61Q19/08; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
132 words
A method of preserving teeth in vivo by decreasing spasm of involuntary contraction in a muscle or group of muscles of a patient induced by pathologic neutral stimulation caused by involuntary jaw clenching, the method comprising: providing a chemodenervating pharmaceutical characterized in that a unit quantity of said pharmaceutical has been determined to denervate a predetermined volume of said muscle or said group of muscles; determining a dose of said pharmaceutical required to denervate the predetermined volume of muscle without inducing significant paresis in muscle tissue adjacent said predetermined volume; and injecting a chemodenervating preparation into at least one of the muscles selected from the group consisting of the masseter, temporalis, and pterygoid in an amount sufficient to diminish involuntary jaw clenching while permitting voluntary muscle stimulation, thereby retarding premature tooth wear.
Claim 2
Independent Claim
132 words
A method of preserving teeth in vivo by decreasing spasm of involuntary contraction in a muscle or group of muscles of a patient induced by pathologic neutral stimulation caused by involuntary jaw clenching, the method comprising: providing a chemodenervating pharmaceutical characterized in that a unit quantity of said pharmaceutical has been determined to denervate a predetermined volume of said muscle or said group of muscles; determining a dose of said pharmaceutical required to denervate the predetermined volume of muscle without inducing significant paresis in muscle tissue adjacent said predetermined volume; and injecting a chemodenervating preparation into at least one of the muscles selected from the group consisting of the masseter, temporalis, and pterygoid in an amount sufficient to diminish involuntary jaw clenching while permitting voluntary muscle stimulation, thereby retarding premature tooth wear.
Claim 3
Independent Claim
121 words
A method of decreasing spasm or involuntary contraction in a muscle or group of muscles of a patient induced by pathologic neural stimulation caused by cerebrospinal injury or stroke, the method comprising: providing a chemodenervating pharmaceutical characterized in that a unit quantity of said pharmaceutical has been determined to denervate a predetermined volume of said muscle or group of muscles; determining a dose of said pharmaceutical required to denervate the predetermined volume of muscle without inducing significant paresis in muscle tissue adjacent said predetermined volume; and injecting directly into said muscle or muscle group of said patient said dose of said pharmaceutical thereby to decrease the spasm or involuntary contraction in said muscle or muscle group while permitting voluntary muscle stimulation.
Claim 4
Independent Claim
121 words
A method of decreasing spasm or involuntary contraction in a muscle or group of muscles of a patient induced by pathologic neural stimulation caused by cerebrospinal injury or stroke, the method comprising: providing a chemodenervating pharmaceutical characterized in that a unit quantity of said pharmaceutical has been determined to denervate a predetermined volume of said muscle or group of muscles; determining a dose of said pharmaceutical required to denervate the predetermined volume of muscle without inducing significant paresis in muscle tissue adjacent said predetermined volume; and injecting directly into said muscle or muscle group of said patient said dose of said pharmaceutical thereby to decrease the spasm or involuntary contraction in said muscle or muscle group while permitting voluntary muscle stimulation.
Claim 5
Dependent Claim
18 words
The method of claim 1 or 2 wherein said denervating preparation comprises a neurotoxin derived from Clostridium botulinum.
References Cited (Backward Citations)
US2979055A
Cited
US3898983A
Cited
US4501582A
Cited
US4331145A
Cited
US4445515A
Cited
US4664911A
Cited
US4522302A
Cited
US4810243A
Cited
US5097834A
Cited
US4880014A
Cited
US4932936A
Cited
US5053005A
Cited
US5183462A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-03-28 | 1997-09-27 | 1998-03-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-03-28 | 2001-09-27 | 2002-03-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-03-28 | 2005-09-27 | 2006-03-29 | $7700.00 | Window Closed / Lapsed |